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Abstract
X-linked agammaglobulinemia (XLA) is a primary
immunodeficiency with more than 600 mutations in
Bruton tyrosine kinase (Bkt) gene which are responsible
for early-onset agammaglobulinemia and repeated
infections. Herein we present a case of a 3-year-old boy
with history of repeated diarrhoea and an episode of
meningoencephalitis with hemiplegia. The workup
showed extremely low levels of immunoglobulin with low
CD+19 cells. Genetic analysis showed Btk mutation 18
c.1883delCp.T628fs. To the best of our knowledge this is
the first report of a case of XLA confirmed by molecular
technique from Pakistan.
Keywords: Bruton type agammaglobulinemia, Bruton
tyrosine Kinase mutation, Whole exome sequencing,
Diarrhoea.
Introduction
X-linked agammaglobulinemia (XLA) /
hypogammaglobulinemia, also known as Bruton's
agammaglobulinemia is a prototype of humoral
immunodeficiency first described by Bruton in 1952.1 It is
an uncommon congenital disease and is the major
primary immunodeficiency recognised in childhood. As
an x-linked recessive disorder, the incidence rate of XLA is
around 0.5/100,000.2 XLA is caused by mutations in the
Bruton tyrosine kinase (Bkt) gene. Patients classically
show less than 2% of the peripheral B cells and decreased
levels of all immunoglobulins3 that influence the affected
patients to repeated, severe bacterial infections,
principally invasive extracellular pyogenic organisms.4
The most common presenting problems are
bronchiectasis, recurrent pneumonia and recurrent upper
respiratory tract infections, including sinusitis, otitis
media and pharyngitis. Btk mutation also plays a key role
in signal transduction of pre-B-cell receptor (BCR). In one
case report, it was noted that XLA is also associated with
precursor B-cell acute lymphoblastic leukaemia, which is
the most common malignancy in children.5 XLA is caused
by 600 different mutations in the Bruton tyrosine kinase
(Bkt) gene. The Bkt gene is mapped on X chromosome at
Xq21.3-Xq22. It has five domains (PH, TH, SH3, SH2, and
TK) and XLA is caused by mutation in all these five
structural domains.6 Herein, we report a case of a child
with repeated diarrhoea since the age of eighteen
months and diagnosed to have XLA with Btk mutation on
gene sequencing.
Case Report
A 3-year-old boy presented to the Emergency
Department at Aga Khan University Hospital in themonth
of January 2013 with complaints of diarrhoea and fever
for 3 days. The child had a significant past history with
recurrent diarrhoea since the age of eighteen months. For
this complaint, he was treated by multiple doctors with
oral and intravenous antibiotics and usually got relief for
few days before becoming symptomatic again. One year
prior to presenting at our department, he had been
hospitalised for one month due to meningoencephalitis
which resulted in right-sided hemiplegia. He was treated
with intravenous antibiotics and physiotherapy. Family
history was also remarkable. He was born to
consanguineous parents and has three sisters and two
brothers, alive. One brother was treated for tuberculosis
(TB). Two elder brothers had died in infancy, one due to
diarrhoea and the other due to pneumonia.
On examination his height and weight were below the
fifth percentile, was moderately dehydrated, and was also
anaemic. No lymphadenopathy or enlarged tonsils were
noted. Systemic examination showed protuberant
abdomen with no visceromegaly. He had decreased
power and tone in the right upper and lower limbs.
Laboratory investigations showed normal absolute
neutrophil count and absolute lymphocyte count, and
hypokalaemia with normal renal function. He was also
screened for TB due to its endemicity in our region and
history of contact but the result was negative. Due to
history of repeated infections and family history of male
deaths, there was a strong suspicion of
immunodeficiency. Evaluation showed markedly low
immunoglobulins: IgG: <0.7, IgM: <0.08, and IgA: <0.15.
Flow cytometry showed undetectable levels of CD+19 B
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cells. Whole genome sequencing showed Btk mutation
with a frame shift deletion 18 c.1883delCp.T628fs.
The child improved on supportive care and antibiotics.
Currently he is on regular intravenous immunoglobulins
(IVIG) replacement and follow-up.
Discussion
XLA is a primary immunodeficiency which is caused by
600 different mutations in the Btk gene. Even though
most of the clinical symptoms develop in childhood,
certain cases may remain undiagnosed or misdiagnosed
as common immunodeficiency, selective IgG or IgA
deficiency as they only show mild
hypogammaglobulinemia and lack recurrent infections in
childhood. In early 1993, germline mutation of Btk gene
was identified as a cause of XLA. These mutations cause
defects in early B cell development.6
The Btk gene is found at Xq21.3-Xq22 and encompasses
37.5 kb that contain 19 exons. Btk belongs to a group of
related cytoplasmic tyrosine kinases, known as the
Btk/Tec family, and comprises of five different structural
domains, which contain the N-terminus, pleckstrin
homology (PH) domain, Tec homology (TH) domain, SRC
homology 3 (SH3) domain, SH2 domain, and the catalytic
kinase (SH1) domain.7,8 Mutations in any domain of the
Btk can induce dysfunction of the Btk protein, block the
development of pre-B cells from naive B cells and reduce
the lifespan ofmature B lymphocytes.9,10 The deficiency of
B lymphocytes and plasmocytes in the peripheral blood
can decrease the synthesis of different immunoglobulins,
reduce precise responses to several antigens, and hence
eventually induce immunodeficiency.11
Flow cytometric analysis using the anti-Btk antibody is a
commanding diagnostic tool for screening XLA patients
to measure Btk expression in peripheral monocytes. It is
used for subsequent genetic counselling, carrier
detection and prenatal diagnosis.12 It is available at some
reference laboratories and efforts should be made to
collaborate with these reference laboratories to aid in
patient counselling as well as identify the spectrum of
primary immunodeficiency in our population. We have
done this with the help of "The Jeffrey Modell
Foundation" Immunology Division, Boston Children's
Hospital.
Existing treatment options for XLA includes lifelong
prophylactic therapy with IVIG that repairs some of the
missing antibodies, suitable antibiotics for prevention of
acute and chronic infections, nutritional rehabilitation
and immunisation. If the disease is diagnosed early,
patients can have a good quality of life. In order to
decrease the recurrences, number of hospital admissions
and severity of infections, early treatment with
immunoglobulin replacement therapy is important.13 Live
viral vaccines should be avoided. Former reports propose
that high dose IVIG replacement therapy (>400 mg/kg
every 3 weeks) is more effective than low-dose
(<200mg/kg) in patients with XLA.14 In our patient we
have given immunoglobulins every 3-4 weeks. His serum
IgG levels were alsomonitored and sustained above 5 g/L.
These therapies are effective; nevertheless they are costly
and non-curative. There is no definitive cure for XLA, yet
the likelihood of using gene-corrected haematopoietic
stem cells to complement the immune defects in mouse
models has been studied. It may be hopeful to initiate
stem cell-based therapy for XLA using gene-corrected
autologous haematopoietic stem cells.15
Conclusion
Flow cytometric assessment of Btk expression in
monocytes may set up a speedy and sensitive approach
for recognition of XLA patients and female carriers, and
support the clinicians to execute IVIG replacement
therapy in an appropriate manner which might
considerably decline the incidence of complications and
the death rate.
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